Immune Mechanisms of HCV Persistence and Pathogenesis
Immune Mechanisms of HCV Persistence and Pathogenesis
批准号:
7342863
负责人:
JIAREN SUN
金额:
$33.33万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-02-01 至 2012-01-31
关键词:
AddressAdenovirusesAdoptedAmericanAnimal ModelAnimal VirusesAnimalsAntigen PresentationAntiviral AgentsAntiviral ResponseAreaBiochemicalBiological AssayBlood CirculationBone MarrowBreedingCD40 AntigensCell physiologyCessation of lifeChimeric ProteinsChronicComplementComplexDiseaseDisease ProgressionElevationEnzymesEpitopesEstrogen ReceptorsFatty LiverFluorescence Resonance Energy TransferFutureGene ExpressionGenesHLA-A2.1HepaticHepatitis CHepatitis C TherapeuticsHepatitis C virusHost DefenseHumanHuman papillomavirus 16 E1 proteinImmuneImmune responseImmune systemImmunologicsImmunosuppressionInfectionInflammationInjuryInterferon-alphaInterferonsLacZ GenesLiverMeasuresMediatingMolecularMusMutateMyelogenousNatural Killer CellsNonstructural ProteinNumbersOutcomePathogenesisPatientsPersonsPhasePolymerase Chain ReactionProcessProductionProphylactic treatmentReceptor GeneReporterResearchResearch PersonnelRoleSeverity of illnessSignaling MoleculeStructural GenesStructural ProteinSystemT-LymphocyteTNFRSF5 geneTamoxifenTechnologyTestingTherapeutic immunosuppressionTimeTransgenesTransgenic MiceTransgenic OrganismsUnited StatesVaccinesViralViral AntigensViral PathogenesisViral ProteinsVirusWestern BlottingWorkbasedefense responsedesignenzyme linked immunospot assaygene inductionimmune functionin vivoinsightintrahepaticliver transplantationmouse modelnovelnovel therapeuticsprotein expressionresearch studyresponsevirus corevirus pathogenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Nearly 4 million Americans are currently infected with hepatitis C virus (HCV). HCV infection is responsible
for approximately 8,000-10,000 deaths annually and is the leading reason for liver transplantation in the
United States. There is no vaccine for the control of hepatitis C. A small number of people infected with.HCV
overcome the virus during the initial infection and clear it from the bloodstream. The remaining 75%-85%
develop a chronic infection. The severity of the disease varies greatly from person to person. The molecular
basis for viral persistence, disease progression and potential virus/host targets for novel therapeutics is not
well understood. We hypothesize that parenchymal HCV antigen presentation leading to inappropriate T cell
function contributes to immune-mediated liver inflammation and that direct immunosuppression by viral
proteins is a component of an integrated strategy of HCV survival. Three complementary approaches will be
used to test these hypotheses: 1) To test the function of immune costimulatory molecules (e.g. CD40) in
HCV-related liver injuries, we will establish a lineage of mice that conditionally express HCV structural
proteins and CD40 molecules in the liver. Pathological changes in the liver, hepatic T cell priming and
effector functions in these mice will be measured by FACS, ELISPOT and immunohistological analyses. 2)
To examine whether HCV nonstructural (NS) proteins, especially NS3, interfere with the host antiviral
responses leading to viral persistence, we will generate mice conditionally expressing HCV-NS genes,
which are controlled by a novel tamoxifen-inducible system. We will examine these animals' interferon
(IFN)-alpha/beta and adaptive immune responses in response to a viral challenge in the liver. Hepatic injury
and viral persistence in these animals will be determined by biochemical, histopathological and
immunochemical, and real-time PCR analyses. 3) Finally, we will examine the synergistic effects of HCV-S
and-NS genes on disease pathogenesis and viral persistence in animals conditionally expressing the entire
HCV genes in the liver. The immunosuppressive effect of the total complement HCV proteins will be tested
following a viral challenge. These studies would provide important information concerning molecular
mechanisms responsible for viral persistence and disease progression in vivo, and may aid in devising
future strategies targeted at blocking specific candidates.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GPR120 regulation of intestinal IgA responses and gut IgA-coated bacteria
-
批准号:10176396
-
项目类别:
-
资助金额:$19.75万
-
财政年份:2020
-
负责人:JIAREN SUN
-
依托单位:
Retinoic Acid Regulates S100 Proteins and Immune Responses in Viral Hepatitis
-
批准号:9169284
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2016
-
负责人:JIAREN SUN
-
依托单位:
Damage-associated Alarmin Key to Immune Responses in Viral Hepatitis
-
批准号:8771220
-
项目类别:
-
资助金额:$23.23万
-
财政年份:2014
-
负责人:JIAREN SUN
-
依托单位:
Immune Mechanisms of HCV Persistence and Pathogenesis
-
批准号:7759108
-
项目类别:
-
资助金额:$33.0万
-
财政年份:2007
-
负责人:JIAREN SUN
-
依托单位:
Immune Mechanisms of HCV Persistence and Pathogenesis
-
批准号:8212128
-
项目类别:
-
资助金额:$32.67万
-
财政年份:2007
-
负责人:JIAREN SUN
-
依托单位:
Immune Mechanisms of HCV Persistence and Pathogenesis
-
批准号:7556368
-
项目类别:
-
资助金额:$33.33万
-
财政年份:2007
-
负责人:JIAREN SUN
-
依托单位:
Immune Mechanisms of HCV Persistence and Pathogenesis
-
批准号:8019445
-
项目类别:
-
资助金额:$32.67万
-
财政年份:2007
-
负责人:JIAREN SUN
-
依托单位:
Immune Mechanisms of HCV Persistence and Pathogenesis
-
批准号:7207478
-
项目类别:
-
资助金额:$33.98万
-
财政年份:2007
-
负责人:JIAREN SUN
-
依托单位:
Immune Costimulatory Molecules in HCV Pathogenesis
-
批准号:6741223
-
项目类别:
-
资助金额:$15.1万
-
财政年份:2003
-
负责人:JIAREN SUN
-
依托单位:
Immune Costimulatory Molecules in HCV Pathogenesis
-
批准号:6804734
-
项目类别:
-
资助金额:$15.1万
-
财政年份:2003
-
负责人:JIAREN SUN
-
依托单位:
海外基金